ABSTRACT
In 2020, CMS updated the ‘Final Rule’ for organ procurement organizations (OPO) in 2020 to include new metrics of OPO performance with a carveout whereby pancreata procured for research count as a “donor” to reward OPOs procuring pancreata for islet cell research or transplantation. Yet data suggested OPOs took advantage of this loophole, leading to updated guidance in 2024 to require OPOs classify whether procured research pancreata were “accepted for islet cell research.” Based on updated data using the new CMS codes, the increase in research pancreas procurement was nearly half previously reported, but far greater than prior to 2020. Importantly, the number of pancreata OPOs reported were accepted for islet cell research were an order of magnitude greater than what was used by the Integrated Islet Cell Distribution Program (IIDP) and the Network for Pancreatic Organ Donors with Diabetes (nPOD), the two largest sources of islet cell/pancreata for qualified researchers in the US. Inappropriate procurement of organs, and mislabeling them as being used for “islet cell research” raises questions of fraud, waste, and abuse that requires further investigation and transprancy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study uses publicly available data, by request, from the OPTN and frm the IIDP website (https://iidp.coh.org/Overview/Program-Statistics)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The OPTN data are available by request from the OPTN, which were made available in aggregate data per OPO per year, and due to the DUA require other investigators request the data from the OPTN. the IIDP data are available on the IIDP website: https://iidp.coh.org/Overview/Program-Statistics
Abbreviations
- (CMS)
- Centers for Medicare and Medicaid Services
- (OPOs)
- Organ procurement organizations
- (OPTN)
- Organ Procurement and Transplantation Network
- (IIDP)
- Integrated Islet Cell Distribution Program
- (nPOD)
- Network for Pancreatic Organ Donors with Diabetes
